Literature DB >> 28537943

Reinforcing effectiveness of midazolam, ethanol, and sucrose: behavioral economic comparison of a mixture relative to its component solutions.

E Andrew Townsend1, Donna M Platt, James K Rowlett, Peter G Roma, Kevin B Freeman.   

Abstract

Benzodiazepines (BZs) are relatively safe when administered alone. However, these drugs can produce severe side effects when coadministered with ethanol. Despite these adverse consequences, rates of concurrent BZ and ethanol misuse are increasing, and it is unclear whether this behavior is maintained by an enhanced reinforcing effect of the mixture. To address this issue, the current study compared the reinforcing effectiveness of sucrose solutions mixed with midazolam, ethanol, or both. Eight male rats were trained to orally self-administer solutions of either sucrose (S), sucrose+midazolam (SM), sucrose+ethanol (SE), or sucrose+midazolam+ethanol (SME). The response requirement was increased between sessions until the number of reinforcers earned was zero and the relationship between response requirement and reinforcers earned was analyzed using the exponential model of demand. Although baseline intake was similar across drug conditions, consumption of SM was least affected by increases in cost, indicating that it possessed the highest reinforcing effectiveness (i.e. least elastic). The reinforcing effectiveness of S, SE, and SME did not differ significantly. The finding that the reinforcing effectiveness of the SME was less than that of SM does not support the supposition that BZ and ethanol coadministration is maintained by a higher reinforcing effectiveness of the mixture.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28537943      PMCID: PMC5648065          DOI: 10.1097/FBP.0000000000000308

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  68 in total

Review 1.  Medications acting on the GABA system in the treatment of alcoholic patients.

Authors:  Fabio Caputo; Mauro Bernardi
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

2.  Effects of GABAergic modulators on food and cocaine self-administration in baboons.

Authors:  Elise M Weerts; Wolfgang Froestl; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2005-07-07       Impact factor: 4.492

3.  Prediction of abuse liability of drugs using IV self-administration by rats.

Authors:  R J Collins; J R Weeks; M M Cooper; P I Good; R R Russell
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

4.  Behavioral tolerance to the force differentiation effects of diazepam and midazolam in rats.

Authors:  S E Bowen; S C Fowler; J A Stanford; M J Kallman
Journal:  Psychopharmacology (Berl)       Date:  2000-03       Impact factor: 4.530

5.  Effect of GABA agonists and GABA-A receptor modulators on cocaine- and food-maintained responding and cocaine discrimination in rats.

Authors:  Andrew C Barrett; S Stevens Negus; Nancy K Mello; S Barak Caine
Journal:  J Pharmacol Exp Ther       Date:  2005-07-20       Impact factor: 4.030

6.  Chlordiazepoxide's interaction with ethanol intake in the rat: relation to ethanol exposure paradigms.

Authors:  T Roehrs; O Yang; H Samson
Journal:  Pharmacol Biochem Behav       Date:  1984-06       Impact factor: 3.533

7.  Ethanol-chlordiazepoxide interactions in the rat.

Authors:  M D Schechter; D M Lovano
Journal:  Pharmacol Biochem Behav       Date:  1985-12       Impact factor: 3.533

8.  Midazolam oral self-administration.

Authors:  J L Falk; M Tang
Journal:  Drug Alcohol Depend       Date:  1985-05       Impact factor: 4.492

9.  Intravenous self-administration of diazepam in rats.

Authors:  T Naruse; T Asami
Journal:  Eur J Pharmacol       Date:  1987-03-31       Impact factor: 4.432

10.  Modification of ethanol's reinforcing effectiveness in rhesus monkeys by cocaine, flunitrazepam, or gamma-hydroxybutyrate.

Authors:  Gail Winger; Chad M Galuska; Steven R Hursh
Journal:  Psychopharmacology (Berl)       Date:  2007-05-18       Impact factor: 4.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.